Stereotactic ablative radiotherapy for early stage non-small cell lung cancer: a critical literature review of predictive factors of relapse

Highlights • Stereotactic ablative radiation therapy (SABR) has become the standard treatment for non-operable patients with early stage non-small cell lung cancer. • Predictive factors have been extensively described in surgical patients. • Knowing such predictive factors for SABR patients could le...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Cancer treatment reviews 2016-11, Vol.50, p.240-246
Hauptverfasser:	Loganadane, Gokoulakrichenane, Martinetti, Florent, Mercier, Olaf, Krhili, Samar, Riet, François-Georges, Mbagui, Rodrigue, To, Hanh, Le Péchoux, Cécile, Levy, Antonin
Format:	Artikel
Sprache:	eng
Schlagworte:	Adenocarcinoma - diagnostic imaging Adenocarcinoma - pathology Adenocarcinoma - radiotherapy Carcinoma, Non-Small-Cell Lung - diagnostic imaging Carcinoma, Non-Small-Cell Lung - pathology Carcinoma, Non-Small-Cell Lung - radiotherapy Carcinoma, Squamous Cell - diagnostic imaging Carcinoma, Squamous Cell - pathology Carcinoma, Squamous Cell - radiotherapy Hematology, Oncology and Palliative Medicine Humans Local relapse Lung cancer Lung Neoplasms - diagnostic imaging Lung Neoplasms - pathology Lung Neoplasms - radiotherapy Neoplasm Recurrence, Local - epidemiology Neoplasm Staging Positron Emission Tomography Computed Tomography Radiosurgery - methods Radiotherapy, Image-Guided Risk Factors Stereotactic ablative radiation therapy (SABR) Stereotactic body radiotherapy (SBRT) Surgery Treatment Outcome Tumor Burden
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Highlights • Stereotactic ablative radiation therapy (SABR) has become the standard treatment for non-operable patients with early stage non-small cell lung cancer. • Predictive factors have been extensively described in surgical patients. • Knowing such predictive factors for SABR patients could lead increasing outcomes and building future trials.
ISSN:	0305-7372 1532-1967
DOI:	10.1016/j.ctrv.2016.10.002